CoChat

Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma

Published version of a preprint

The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.

Abstract

Purpose: We evaluated the predictive and prognostic value of circulating tumor DNA (ctDNA) in patients with Ewing sarcoma (EWS) treated in the EWING2008 trial. Experimental Design: Plasma samples from 102 patients with EWS enrolled in the EWING2008 trial were obtained before and during induction chemotherapy. Genomic EWSR1 fusion sequence spanning primers and probes were used for highly specific and sensitive quantification of the levels of ctDNA by digital droplet PCR. ctDNA levels were correlated to established clinical risk factors and outcome parameters. Results: Pretreatment ctDNA copy numbers were correlated with event-free and overall survival. The reduction in ctDNA levels below the detection limit was observed in most cases after only two blocks of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) induction chemotherapy. The persistence of ctDNA after two VIDE blocks was a strong predictor of poor outcomes. ctDNA levels correlated well with most established clinical risk factors; an inverse correlation was found only for the histologic response to induction therapy. ctDNA levels did not provide simple representations of tumor volume, but integrated information from various tumor characteristics represented an independent EWS tumor marker with predictive and prognostic value. Conclusions: ctDNA copy number in the plasma of patients with EWS is a quantifiable parameter for early risk stratification and can be used as a dynamic noninvasive biomarker for early prediction of treatment response and outcome of patients.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-21-1324

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Cited by

See all 45

Metadata

Authors
Krumbholz, M., Eiblwieser, J., Ranft, A., Zierk, J., Schmidkonz, C., Stütz, A. M., Peneder, P., Tomazou, E. M., Agaimy, A., Bäuerle, T., Hartmann, W., Dirksen, U., & Metzler, M.
Affiliations
  • Universitätsklinikum Erlangen (DE)
  • Essen University Hospital (DE)
  • St. Anna Children's Cancer Research Institute (AT)
  • University Hospital Münster (DE)
Corresponding author
Krumbholz, Manuela
Venue
Clinical Cancer Research
Published
2021-08-23
Volume
27
Issue
21
Pages
5922-5930
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3193636501
Cited by
39
References
43
Citations by year
2026: 8 · 2025: 10 · 2024: 5 · 2023: 9 · 2022: 7
FWCI
3.40
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
Funders
  • EURO EWING Consortium (602856)
  • German Cancer Aid (108128, 70113419, 70112018)
  • EraNet consortium PROspective VAlidation of Biomarkers in Ewing Sarcoma (01KT1310)
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Keywords
Ewing sarcoma, circulating tumor DNA, ctDNA quantification, fusion transcripts, droplet digital PCR, treatment response prediction, risk stratification, prognostic factors, event-free survival, overall survival, non-invasive biomarkers
MeSH terms
Circulating Tumor DNA, Adolescent, Adult, Antineoplastic Agents, Bone Neoplasms, Child, Child, Preschool, Female, Humans, Male, Predictive Value of Tests, Prognosis, Sarcoma, Ewing, Time Factors, Translocation, Genetic, Treatment Outcome, Risk Assessment, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-21-1324
The paper
Krumbholz, M., Eiblwieser, J., Ranft, A., Zierk, J., Schmidkonz, C., Stütz, A. M., Peneder, P., Tomazou, E. M., Agaimy, A., Bäuerle, T., Hartmann, W., Dirksen, U., & Metzler, M. (2021). Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-21-1324

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.